Literature DB >> 30840193

Comparison of Non-routine Healthcare Utilization in the 2 years Following Roux-En-Y Gastric Bypass and Sleeve Gastrectomy: A Cohort Study.

Richard L Seip1, Kyle Robey1, Andrea Stone1, Geneth Chin1, Ilene Staff2, Tara McLaughlin3,4, Darren Tishler1, Pavlos Papasavas1.   

Abstract

BACKGROUND: Patients undergoing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) have different healthcare needs after surgery. Our aim was to quantify non-routine healthcare utilization after RYGB vs. SG.
METHODS: We compared non-routine (NR) visits made and associated services provided up to 2 years post-surgery for patients undergoing RYGB or SG at a Bariatric Surgery Comprehensive Center between March 2013 and April 2015.
RESULTS: A total of 258 and 461 patients had primary RYGB and SG, respectively. Successful follow-up rates at one (76.2%) and 2 years post-surgery (52.6%) did not differ between groups. Rates for all NR visits, expressed as the number per 100 patients, were 68.6 in RYGB vs. 35.4 in SG patients (p < 0.0001). Emergency department visits with subsequent admission (EDA) or without subsequent admission (ED-only) and outpatient visits (OPV) were more frequent in RYGB vs. SG: EDA, 14.7 vs. 8.0 (p = 0.0076); ED-only, 17.8 vs. 7.6 (p = 0.0001); and OPV, 29.8 vs. 14.1 (p < 0.0001). RYGB required more services per 100 patients than SG, 120.9 vs. 75.3, respectively (p < 0.0001). Imaging was the resource most often used overall. Surgery type (RYGB) significantly predicted healthcare utilization even after controlling for gender, ethnicity, and other variables. Healthcare utilization peaked at 1 to 6 months post-surgery, driven by patients who underwent RYGB.
CONCLUSIONS: RYGB required twice as many non-routine follow-up visits and 1.6 times greater use of healthcare services relative to SG. Computer-assisted tomography imaging and endoscopies showed the greatest differences. Peak healthcare utilization for RYGB occurred between 1 and 6 months following surgery.

Entities:  

Keywords:  Bariatric surgery; Follow-up; Healthcare services; Imaging; Non-routine visits

Mesh:

Year:  2019        PMID: 30840193     DOI: 10.1007/s11695-019-03793-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  17 in total

1.  A meta-analysis of 2-year effect after surgery: laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for morbid obesity and diabetes mellitus.

Authors:  Chengda Zhang; Yuan Yuan; Cuiqiong Qiu; Weidong Zhang
Journal:  Obes Surg       Date:  2014-09       Impact factor: 4.129

2.  Emergency department visits and readmissions within 1 year of bariatric surgery: A statewide analysis using hospital discharge records.

Authors:  Maria C Mora-Pinzon; Dana Henkel; Richard E Miller; Patrick L Remington; Jon C Gould; Shanu N Kothari; Luke M Funk
Journal:  Surgery       Date:  2017-07-26       Impact factor: 3.982

3.  Characterizing Readmissions After Bariatric Surgery.

Authors:  Trit Garg; Ulysses Rosas; Daniel Rogan; Harrison Hines; Homero Rivas; John M Morton; Dan Azagury
Journal:  J Gastrointest Surg       Date:  2016-09-09       Impact factor: 3.452

4.  First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass.

Authors:  Matthew M Hutter; Bruce D Schirmer; Daniel B Jones; Clifford Y Ko; Mark E Cohen; Ryan P Merkow; Ninh T Nguyen
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

5.  Causes of small bowel obstruction after Roux-en-Y gastric bypass: a review of 2,395 cases at a single institution.

Authors:  Luke Elms; Rena C Moon; Sheila Varnadore; Andre F Teixeira; Muhammad A Jawad
Journal:  Surg Endosc       Date:  2014-01-01       Impact factor: 4.584

6.  Abdominal imaging post bariatric surgery: predictors, usage and utility.

Authors:  Dana Haddad; Aruna David; Haneen Abdel-Dayem; Nicholas Socci; Leaque Ahmed; Anthony Gilet
Journal:  Surg Obes Relat Dis       Date:  2017-04-29       Impact factor: 4.734

7.  The comparative effectiveness of sleeve gastrectomy, gastric bypass, and adjustable gastric banding procedures for the treatment of morbid obesity.

Authors:  Arthur M Carlin; Telal M Zeni; Wayne J English; Abdelkader A Hawasli; Jeffrey A Genaw; Kevin R Krause; Jon L Schram; Kerry L Kole; Jonathan F Finks; John D Birkmeyer; David Share; Nancy J O Birkmeyer
Journal:  Ann Surg       Date:  2013-05       Impact factor: 12.969

8.  Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin.

Authors:  Arthur Bohdjalian; Felix B Langer; Soheila Shakeri-Leidenmühler; Lisa Gfrerer; Bernhard Ludvik; Johannes Zacherl; Gerhard Prager
Journal:  Obes Surg       Date:  2010-01-22       Impact factor: 4.129

9.  Indications and Operative Outcomes of Gastric Bypass Reversal.

Authors:  Hinali Zaveri; Ramsey M Dallal; Daniel Cottam; Amit Surve; Susan Kartiko; Fernando Bonnani; Austin Cottam; Samuel Cottam
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

Review 10.  Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy to Treat Morbid Obesity-Related Comorbidities: a Systematic Review and Meta-analysis.

Authors:  Jianfang Li; Dandan Lai; Dongping Wu
Journal:  Obes Surg       Date:  2016-02       Impact factor: 4.129

View more
  2 in total

1.  Relationship Between Bariatric Surgery and Gastroesophageal Reflux Disease: a Systematic Review and Meta-analysis.

Authors:  Lihu Gu; Bangsheng Chen; Nannan Du; Rongrong Fu; Xiaojing Huang; Feiyan Mao; Parikshit Asutosh Khadaroo; Shenbiao Zhao
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

2.  Comparison of Ambulatory Health Care Costs and Use Associated With Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy.

Authors:  Kristina H Lewis; Stephanie Argetsinger; David E Arterburn; Jenna Clemenzi; Fang Zhang; Ronald Kamusiime; Adolfo Fernandez; Dennis Ross-Degnan; James F Wharam
Journal:  JAMA Netw Open       Date:  2022-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.